Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2003 OR
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _______ to
Commission File Number
Pharmacy Buying Association, Inc.
(Exact name of registrant as specified in its charter)
Missouri 43-1482785
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1575 N. Universal Ave., Suite 100, Kansas City, Missouri 64120
(Address of principal executive offices) (Zip Code)
(816) 245-5700
Registrant's telephone number, including area code
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No|_|
At June 30, 2003, 11,380 shares of common stock, $1.00 par value, of the
registrant were outstanding.
Total number of pages 14.
Pharmacy Buying Association, Inc.
INDEX FORM 10-Q
Page No.
--------
Part I - FINANCIAL INFORMATION 2
ITEM 1 - FINANCIAL STATEMENTS 2
Consolidated Balance Sheets as of June 30, 2003
(unaudited and December 31, 2002 3
Consolidated Statements of Operations for the three and
six months ended June 30, 2003 and 2002(unaudited) 4
Consolidated Statements of Cash Flows for the six
months ended June 30, 2003 and 2002(unaudited) 5
Notes to Consolidated Financial Statements (unaudited) 6
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS
OF OPERATIONS AND FINANCIAL CONDITION 8
ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK 12
Part II - OTHER INFORMATION 13
ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K 13
SIGNATURES 14
EXHIBITS 15
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
PHARMACY BUYING ASSOCIATION, INC. AND SUBSIDIARY
D/B/A TRUECARE PHARMACY
INDEX TO FINANCIAL STATEMENTS
Consolidated financial statements:
Consolidated balance sheets as of June 30, 2003 (unaudited)
and December 31, 2002
Consolidated statements of operations for the three and six
months ended June 30, 2003 and 2002 (unaudited)
Consolidated statements of cash flows for the six months ended
June 30, 2003 and 2002 (unaudited)
Notes to consolidated financial statements (unaudited)
PHARMACY BUYING ASSOCIATION, INC. AND SUBSIDIARY
D/B/A TRUECARE PHARMACY
CONSOLIDATED BALANCE SHEETS
ASSETS
(Unaudited)
June 30, December 31,
2003 2002
------------ ------------
Current assets:
Accounts receivable $ 7,813,176 $ 8,138,869
Inventories 8,564,668 8,185,885
Prepaid expenses 134,730 152,374
Refundable income taxes 143,759
------------ ------------
Total current assets 16,656,333 16,477,128
Investment 500,000 500,000
Property and equipment 403,108 453,109
Goodwill 229,144 229,144
Other assets 17,890 17,890
------------ ------------
$ 17,806,475 $ 17,677,271
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Checks written in excess of cash in bank $ 91,092 $ 321,386
Bank line of credit 3,000,000
Accounts payable 11,012,878 7,083,642
Accrued payroll 73,853 81,978
Deferred revenue 153,240 282,200
Income taxes payable 159,356
Deferred income taxes 101,000 101,000
------------ ------------
Total current liabilities 11,432,063 11,029,562
------------ ------------
Deferred income taxes 7,000 7,000
------------ ------------
Commitments and contingencies
Stockholders' equity:
Common stock, $1 par; authorized 30,000
shares; issued 11,380 shares 11,380 11,380
Capital in excess of par value 1,468,255 1,468,255
Retained earnings 6,012,859 5,363,178
------------ ------------
7,492,494 6,842,813
Treasury stock at cost, 1,947 shares at June 30, 2003
and 358 shares at December 31, 2002 (1,125,082) (202,104)
------------ ------------
6,367,412 6,640,709
------------ ------------
$ 17,806,475 $ 17,677,271
============ ============
See notes to consolidated financial statements.
PHARMACY BUYING ASSOCIATION, INC. AND SUBSIDIARY
D/B/A TRUECARE PHARMACY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three months ended Six months ended
June 30, June 30,
-------- --------
2003 2002 2003 2002
---- ---- ---- ----
Revenues:
Distribution center (including revenues
generated from businesses owned by
members of the Board of Directors of
$4,158,079 and $4,449,504 for the three
months ended June 30, 2003 and 2002,
respectively, and $7,973,047, and
$8,345,856 for the six months ended
June 30, 2003 and 2002, respectively $ 37,662,506 $ 31,538,631 $ 74,356,555 $ 56,032,781
Participation programs and fees 700,844 210,439 1,581,454 378,130
Activity rebates and charges 1,711,548 1,938,752 3,219,684 3,676,916
Third party 34,557 11,469 60,258 11,958
------------ ------------ ------------ ------------
40,109,455 33,699,291 79,217,951 60,099,785
------------ ------------ ------------ ------------
Cost of revenues:
Distribution center 36,627,758 30,085,912 72,094,929 53,544,221
Participation programs and fees 415,761 136,502 621,104 311,409
Activity rebates 1,076,780 1,164,687 2,404,768 2,138,540
------------ ------------ ------------ ------------
38,120,299 31,387,101 75,120,801 55,994,170
------------ ------------ ------------ ------------
Gross profit 1,989,156 2,312,190 4,097,150 4,105,615
General and administrative expenses 1,577,811 1,246,894 3,001,832 2,609,180
------------ ------------ ------------ ------------
Income from operations 411,345 1,065,296 1,095,318 1,496,435
------------ ------------ ------------ ------------
Other income (expense):
Investment income 3,626 6,678 7,548 10,642
Interest expense (207) (4,159) (1,712) (6,510)
Gain on disposal of assets 4,786 4,786
------------ ------------ ------------ ------------
3,419 7,305 5,836 8,918
------------ ------------ ------------ ------------
Income before income taxes 414,764 1,072,601 1,101,154 1,505,353
Income taxes 170,883 363,422 451,473 535,989
------------ ------------ ------------ ------------
Net income $ 243,881 $ 709,179 $ 649,681 $ 969,364
============ ============ ============ ============
Earnings per common share:
Income available to common
stockholders $ 243,881 $ 709,179 $ 649,681 $ 969,364
Weighted average shares outstanding,
basic and diluted 10,338 11,373 10,643 11,373
------------ ------------ ------------ ------------
Basic and diluted earnings per share $ 23.59 $ 62.36 $ 61.04 $ 85.23
============ ============ ============ ============
See notes to consolidated financial statements.
PHARMACY BUYING ASSOCIATION, INC. AND SUBSIDIARY
D/B/A TRUECARE PHARMACY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six months ended June 30,
2003 2002
---- ----
Cash flows from operating activities:
Net income $ 649,681 $ 969,364
Adjustments to reconcile net income to net
cash used by operating activities:
Depreciation 102,669 117,349
Deferred income taxes (119,000)
Gain on sale of property and equipment (4,786)
Changes in operating assets and liabilities:
Accounts receivable 325,693 (506,200)
Inventories (378,783) (2,026,883)
Prepaid expenses 17,644 33,085
Refundable income taxes (143,759)
Other assets (22,314)
Checks written in excess of cash (230,294)
Accounts payable 3,929,236 1,764,491
Accrued payroll (8,125) (14,538)
Deferred revenue (128,960) (88,367)
Income taxes payable (159,356) (500,087)
----------- -----------
Net cash provided (used) by
operating activities 3,975,646 (397,886)
----------- -----------
Cash flows from investing activities:
Purchase of property and equipment (52,668) (40,938)
Proceeds from sale of property and equipment 10,300
----------- -----------
Net cash used by investing activities (52,668) (30,638)
----------- -----------
Cash flows from financing activities:
Repayment of bank line of credit (3,000,000)
Acquisition of common stock (922,978) (10,232)
Principal payments on long-term debt (25,753)
----------- -----------
Net cash used by financing activities (3,922,978) (35,985)
----------- -----------
Net decrease in cash -- (464,509)
Cash, beginning of period -- 614,519
----------- -----------
Cash, end of period $ -- $ 150,010
=========== ===========
Supplemental disclosures of cash flow information:
Cash transactions during the period for:
Interest paid $ 1,712 $ 6,510
=========== ===========
Income taxes paid $ 754,588 $ 1,155,076
=========== ===========
See notes to consolidated financial statements.
PHARMACY BUYING ASSOCIATION, INC. AND SUBSIDIARY
D/B/A TRUECARE PHARMACY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Basis of presentation:
The accompanying interim financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange
Commission for interim reporting and do not include certain disclosures
required by accounting principles generally accepted in the United States
of America. Accordingly, the statements should be read in conjunction with
the Pharmacy Buying Association, Inc., d/b/a TrueCare Pharmacy (the
Company) financial statements and notes thereto included in the Company's
Annual Report and Form 10-K filed with the Securities and Exchange
Commission under File No. 000-49785. Accounting policies utilized in the
preparation of financial information herein presented are the same as set
forth in our annual financial statements. Certain disclosures and
information normally included in financial statements have been condensed
or omitted. In the opinion of the management of the Company, these
financial statements contain all adjustments (consisting only of normal
recurring adjustments) necessary for a fair presentation of the interim
financial statements. Interim results of operations are not necessarily
indicative of the results of operations for the full year.
2. New accounting standards:
In May 2003, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 150, "Accounting
for Certain Financial Instruments with Characteristics of both Liabilities
and Equity." SFAS No. 150 clarifies the definition of a liability as
currently defined in FASB Concepts Statement No. 6, "Elements of Financial
Statements," as well as other planned revisions. This statement requires a
financial instrument that embodies an obligation of an issuer to be
classified as a liability. In addition, the statement establishes
standards for the initial and subsequent measurement of these financial
instruments and disclosure requirements. SFAS No. 150 is effective for
financial instruments entered into or modified after May 31, 2003 and for
all other matters, at the beginning of our second quarter 2004. We do not
believe the adoption of this standard will have a material impact on our
consolidated financial statements.
In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement 133
on Derivative Instruments and Hedging Activities." SFAS No. 149 amends
SFAS No. 133 for decisions made as part of the FASB's Derivatives
Implementation Group process, other FASB projects dealing with financial
instruments, and in connection with implementation issues raised in
relation to the application of the definition of a derivative. This
statement is generally effective for contracts entered into or modified
after June 30, 2003 and for hedging relationships designated after June
30, 2003. We do not believe the adoption of this standard will have a
material impact on our consolidated financial statements.
In January 2003, the FASB issued Interpretation ("FIN") No. 46,
"Consolidation of Variable Interest Entities." This interpretation
clarifies the application of Accounting Research Bulletin No. 51,
"Consolidated Financial Statements," in determining whether a reporting
entity should consolidate certain legal entities, including partnerships,
limited liability companies, or trusts, among others, collectively defined
as variable interest entities ("VIEs"). This interpretation applies to
VIEs created or obtained after January 31, 2003, and as of July 1, 2003,
to VIEs in which an enterprise holds a variable interest that it acquired
before February 1, 2003. We do not believe that this standard will have a
material impact on our consolidated financial statements.
PHARMACY BUYING ASSOCIATION, INC. AND SUBSIDIARY
D/B/A TRUECARE PHARMACY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(Unaudited)
2. New accounting standards (continued):
In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation-Transition and Disclosure." This statement amends
SFAS No. 123, "Accounting for Stock-Based Compensation," to provide
alternative methods of transition for a voluntary change to the fair value
based method of accounting for stock-based employee compensation. In
addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123
to require prominent disclosures in both annual and interim financial
statements about the method of accounting for stock-based employee
compensation and the effect of the method used on reported results. We do
not believe the adoption of this standard will have a material impact on
our consolidated financial statements.
3. Accounts receivable:
June 30, December 31,
2003 2002
---- ----
Membership $ 1,483,415 $ 1,531,471
Distribution center 6,521,378 6,801,398
----------- -----------
8,004,793 8,332,869
Allowance for doubtful accounts (191,617) (194,000)
----------- -----------
$ 7,813,176 $ 8,138,869
=========== ===========
4. Property and equipment:
June 30, December 31,
2003 2002
---- ----
Furniture and fixtures $ 331,976 $ 298,809
Equipment 730,570 713,516
Software 402,809 400,362
----------- -----------
1,465,355 1,412,687
Accumulated depreciation (1,062,247) (959,578)
----------- -----------
$ 403,108 $ 453,109
=========== ===========
Depreciation expense, included in general and administrative expenses, was
$102,669 and $117,349 for the six-month periods ended June 30, 2003 and
2002, respectively.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion of our financial condition and results of operations
should be read in conjunction with the financial statements and notes thereto
included in elsewhere in this filing.
This discussion and analysis should be read in conjunction with management's
discussion and analysis included in the Company's Form 10-K for the year ended
December 31, 2002 and the Company's Form 10-Q for the first quarter ended March
31, 2003 also contained therein.
Overview
We derive revenues from the following four sources:
Distribution Center. We sell pharmaceutical-related products to our members
through our own distribution facility located in Riverside, Missouri.
Activity Rebates and Charges. We receive rebates from pharmaceutical
manufacturers based on member purchases of the manufacturer's product from our
distribution center. In addition, each of our wholesaler-partner contracts
provides that the wholesaler-partner will pay us a rebate based on a percentage,
which varies by wholesaler-partner, of the dollar value of products purchased by
our members from the wholesaler-partner. We also receive rebates and fees from
other vendors and manufacturers through various company programs, such as our
cash card and drug formularies. These rebates and fees are typically paid to us
on either a quarterly or monthly basis.
Participation Programs and Fees. Our members pay us a monthly membership fee in
accordance with our membership agreement. In addition, we receive administration
fees from manufacturers and wholesaler-partners for maintenance and facilitation
of contracts with us and with our members. Our vendors and members also pay a
fee to attend our annual conference each summer.
Third Party Revenues. Revenues from our third party segment, shown net of
expenses for all reporting periods, are generated from claims costs of goods,
claims processing fees per paid claim charged to plan sponsors, and rebate
administration fees. A major portion of the revenue includes the claims costs of
goods that is collected from the plan sponsor in order to pay the participating
network provider. After payout of claims and expenses, there is usually little
or no net income generated from this revenue.
Our expenses are categorized as follows:
Distribution Center. Operating expenses associated with distribution are
primarily composed of direct cost of goods sold.
Activity Rebates. Rebates are composed of monies paid to members on a quarterly
basis for purchases through the distribution center, purchases made under
contract with wholesaler-partners, cash card claims, and rebates attributable to
fluctuations in the market share of certain pharmaceuticals.
Participation Program and Fees. Program costs and expenses are primarily
composed of expenses associated with the programs and services that we offer to
our members, including the costs of developing and marketing those services. In
addition, costs associated with our annual shareholders conference are included.
General and Administrative Expenses. General and administrative expenses are
typical, non-operating expenses primarily composed of such items as salaries and
wages, insurance, freight and postage, office rent, travel, and other
miscellaneous expenses.
Results of Operation
The following discussion is based on our historical results of operations for
the six months ending June 30, 2003 and 2002.
Comparison of Six Months ending June 30, 2003 and 2002
Revenues
Total Revenues. Total revenues for the six months ending June 30, 2003 increased
to $79.2 million from $60.1 million over the same period revenues in 2002. The
increase of $19.1 million is attributable to a corresponding increase in the
amount of sales through the distribution center.
Distribution. Revenue from distribution grew from $56.0 million to $74.3
million, representing a 33% increase over the same period in 2002. An increase
in product offering combined with a rising usage of the distribution center by
member pharmacies led to the increase in distribution sales.
Activity Rebates and Charges. Revenues due to rebates and charges decreased from
$3.7 million for the six months ending June 30, 2002 to $3.2 million for the
same period in 2003. The decrease in rebate revenue is directly correspondent to
decreasing rebate incentives being offered by manufacturers on certain programs
that are utilized by our member pharmacies.
Participation Programs and Fees. For the six months ending June 30, 2003,
revenues from participation programs and fees increased by $1.2 million from the
corresponding period in 2002. The increase was prompted by a substantial
increase in claims submitted and rebate dollars made available by manufacturers
on our cash card program.
Third Party. Revenues from third party operations, which are shown net of
expenses, increased by approximately $48,000 for the six months ending June 30,
2003 from the same period in 2002. The increase arose primarily from a decrease
in expenses in third party programs.
Cost of Revenues
Distribution Center. Costs of goods sold through the distribution center
increased from $53.5 million for the six months ending June 30, 2002 to $72.1
million in 2003. The 35% increase is directly attributable to the increase in
sales through the distribution center.
Activity Rebates. Rebates increased from $2.1 million in the first six months of
2002 to $2.4 million in the corresponding period of 2003. The increase in
rebates stems from an increase in purchases through our distribution center and
the corresponding rebates. In addition, slightly more aggressive rebate
incentives offered to our pharmacies through the distribution center resulted in
higher rebate expense.
Participation Programs and Fees. Expenses associated with our programs increased
by $310,000 for the six months ending June 30, 2003 compared to the same period
in 2002. The increase in expenses was the result of an increase
in processing fees for our cash card program and expenses associated with our
annual conference, which was held in the first half of the year instead of later
in the year as has been our practice.
General and Administrative. General and administrative expenses rose by $0.39
million for the six months ending June 30, 2003 compared to the same period in
2002. The increase of 18% from $2.6 million to $3.0 million is attributable to a
normal increase in expenses associated with an increase in revenues, including
an increase in warehouse costs, information technology costs, and salaries and
wages.
Income from Operations. Net income from operations decreased by $0.40 million
from $1.5 million for the six months ending June 30, 2002 to $1.1 million for
the same period in 2003. This 27% decrease is attributable to a modest decrease
in gross margins and a modest increase in general and administrative expenses,
both discussed above.
Income Taxes. Income tax expense for the six months ending June 30, 2003
decreased to $0.45 million from $0.53 million for the same period in 2002. The
$85,000 decrease follows directly from a decrease in our taxable income and
lower profitability.
Comparison of Three Months ending June 30, 2003 and 2002
Revenues
Total Revenues. 2nd Quarter 2003 saw total revenues increase to $40.1 million
from $33.7 million over the same period revenues in 2002. The increase of $6.4
million is attributable to a corresponding increase in the amount of sales
through the distribution center.
Distribution. For 2nd Quarter 2003, revenues grew from $31.5 million to $37.7
million, representing a 20% increase over the same period in 2002. An increase
in product offering combined with a rising usage of the distribution center by
member pharmacies led to the increase in distribution sales.
Activity Rebates and Charges. Revenues due to rebates and charges retreated from
$1.9 million in the 2nd Quarter of 2002 to $1.7 million in the 2nd Quarter 2003.
The slight decrease in rebate revenue is directly correspondent to decreasing
rebate incentives being offered by manufacturers on certain programs that are
utilized by our member pharmacies.
Participation Programs and Fees. For 2nd Quarter 2003, revenues from
participation programs and fees increased by $0.49 million from the
corresponding period in 2002. The increase was prompted by a substantial
increase in claims submitted and incentive dollars made available by
manufacturers on our cash card program along with monies collected toward our
annual conference.
Third Party. Revenues from third party operations, which are shown net of
expenses, increased by approximately $23,000 from the 2nd Quarter 2002 to the
2nd Quarter 2003. The increase arises primarily from a decrease in expenses in
third party programs.
Cost of Revenues
Distribution Center. Costs of goods sold through the distribution center
increased from $30.1 million in the 2nd Quarter of 2002 to $36.6 million in the
2nd Quarter of 2003. The 22% increase is directly attributable to the increase
in sales through the distribution center.
Activity Rebates. Rebates decreased slightly from $1.2 million in the 2nd
Quarter of 2002 to $1.1 million in the corresponding period of 2003. The mild
decrease stems from an increasing number of generic drugs being introduced into
the market without any significant form of rebate available. Therefore, we are
unable to provide our member pharmacies with a rebate on those products.
Participation Programs and Fees. Expenses associated with our programs increased
by $279,000 in the 2nd Quarter of 2003 compared to the 2nd Quarter of 2002. The
substantial increase in expenses is a result of a substantial increase in claims
submitted and incentive dollars shared back to our members on our cash card
program along with monies expended toward our annual conference.
General and Administrative. General and administrative expenses rose from $1.2
million in the 2nd Quarter of 2002 to $1.6 million in the 2nd Quarter of 2003.
The increase of 26% is attributable to a normal increase in expenses associated
with an increase in revenues and operations, including an increase in warehouse
costs, information technology costs, and salaries and wages.
Income from Operations. Net income from operations decreased by $0.65 million
from 2nd Quarter 2002 to 2nd Quarter 2003. This 61% decrease is attributable to
decreasing rebate incentives and increases in general and administrative
expenses, both described above.
Income Taxes. 2nd Quarter 2003 Income tax expense decreased by $0.19 million
compared to 2nd Quarter 2002. The decrease is directly attributable to a
decrease in taxable income of approximately $0.65 million for the comparative
periods.
Liquidity and Capital Resources
Our capital requirements relate primarily to working capital for day-to-day
operations, including general and administrative expenses, maintenance of
product inventory levels to fulfill our operating commitment to our members and
membership rebates. Historically, we have financed our cash requirements from
three primary sources: on-going operations, sales of our common stock, and
borrowings under our line of credit.
For the six months ending June 30, 2003:
o Net cash provided by (used by) operations was $4.0 million, compared
to ($0.40 million) for the same period in 2002, primarily due to a
substantial increase in our accounts payable and a slight decrease
in our accounts receivables. A modest increase in inventories and
cash expended for income taxes partially offset the inflow from
operations.
o Net cash (used by) investing activities was ($53,000), compared to
($30,000) in the same period in 2002, primarily attributable to the
purchase of property and equipment.
o Net cash provided by (used by) financing activities was ($3.9
million), compared to ($36,000) for the same period in 2002,
primarily as a result of repayments on our line of credit of $3
million and the repurchase of common stock.
We have a $5 million line of credit and a $2 million additional seasonal
extension from November 1 through February 1 (the "Credit Agreement") with Bank
of America, N.A. that expires on June 30, 2004. Borrowings under the Credit
Agreement bear interest at the lender's prime rate, which was 4.50% as of June
30, 2003. The Credit Agreement imposes certain requirements on us, including the
maintenance of a minimum tangible net worth. We accessed our line of credit from
time to time during 2003. There were no amounts outstanding under the Credit
Agreement as of June 30, 2003. We anticipate renewing the credit agreement or
obtaining a new bank line of credit upon expiration of our current Credit
Agreement.
Cash and cash equivalents as of June 30, 2003 were flat from the beginning of
the year. The June 30, 2003 balance is lower than the cash and cash equivalents
balance for the six months ending June 30, 2002, which was $150,000. We believe
that our cash equivalents as of June 30, 2003, amounts available under the
Credit Agreement, and operating cash flows will be sufficient to meet our
anticipated capital expenditure requirements at least through the next 12
months. Currently, our anticipated capital expenditures are composed of ongoing
day-to-day operations, including normal general and administrative expenses,
maintenance of adequate inventory levels to satisfy our product orders and
income taxes. If sales through our distribution center continue to grow, we will
be using significant portions of our capital going forward to support our
product inventory levels. Except as set forth above, we do not currently
anticipate incurring any expenses or capital expenditures outside the ordinary
course of business.
Because we are registering our common stock under the Securities Exchange Act of
1934, our ability to issue additional shares is more limited because certain
securities exemptions previously relied on by us are not available to issuers
registered under the Exchange Act. Accordingly, any further issuances of common
stock may require registration under the Securities Act of 1933, making it more
costly and time consuming to issue shares. To the extent we are unable to renew
our existing Credit Agreement or obtain a new bank line of credit or raise funds
through the sale of common stock, our ability to increase or maintain our
current level of operations, including product inventory levels, may be
diminished. In addition, we may not be able to obtain additional capital in
adequate amounts or acceptable terms to meet demands of our business in the
future. This would have an adverse effect on our operations and financial
condition.
Forward Looking Statements
This report contains forward looking statements based on our current
expectations and assumptions regarding our business and our industry. Actual
results may differ materially from those described in the forward looking
statements and will be affected by a variety of known and unknown risks,
uncertainties and other factors.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are exposed to market risks primarily from changes in U.S. interest rates. We
do not engage in financial transactions for trading or speculative purposes.
The interest payable on our Credit Agreement is based on variable interest rates
and is therefore affected by changes in market interest rates. While as of June
30, 2003, no amounts were outstanding under the Credit Agreement, to the extent
interest rates rise when we do borrow money under the Credit Agreement, our
interest expense will increase.
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
The following exhibits are filed as part of this report.
1. Certification Pursuant to 18 U.S.C. Section 1350, As Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, signed by
the Chief Executive Officer.
2. Certification Pursuant to 18 U.S.C. Section 1350, As Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, signed by
the Chief Financial Officer.
Exhibit numbers refer to the paragraph numbers under Item 601 of
Regulation S-K:
15.1. Letter from House Park & Dobratz, P.C. regarding unaudited
interim financial information. (Commission File No. 000-49785).
(b) Reports on Form 8-K
The Company did not file a report on Form 8-K during the quarter for
which this report is filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized.
Pharmacy Buying Association, Inc.
Date: August 17, 2003 By: /s/ Donald E. Raby II
-----------------------------------------
Donald E. Raby II, CPA
Vice President, Chief Financial Officer